Mehmet Ali ERKURT, Emin KAYA, Emine HİDAYET, İrfan KUKU, Ayşe UYSAL, İlhami BERBER, Soykan BİÇİM, Ahmet KAYA, Ahmet SARICI, Mustafa ÖZGÜL

Etiological evaluation and the role of plasma exchange treatment in trombotic microangiopathies: A retrospective analysis from Eastern Anatolia

The aim is this study was to make the etiological classification of patients diagnosed with TMA in our region and to statistically evaluate the effect of therapeutic plasma exchange, which we use in treatment, on laboratory recovery and mortality. In our study, between 2009-2017, 85 patients diagnosed with TMA in our center evaluated retrospectively. Thirty- one (36.5%) of our patients were followed up with HELLP, 23 with thrombotic thrombocytopenic purpura (TTP) (27.1%), 20 (23.5%) snake bites, and 11 (12.9%) with atypical hemolytic uremic syndrome (aHUS). TPE treatment was performed in all patients. TPE treatment was found effective in patients with HELLP syndrome, TTP and snake bite and statistically significant improvement was obtained in laboratory parameters (p0.05). Mortality rates were found 9.7%, 21.7%, 27.3%, and 0% in patients with HELLP Syndrome, TTP, aHUS, and snake bite, respectively. The primary treatment in HELLP syndrome was termination of pregnancy, it was observed in our study that TPE was effective in TTP, HELLP syndrome and snake bites and treatment should be started without delay

PDF

___

1. Tsai HM. Untying the knot of thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome. Am J Med 2013;126:200-9. 2. George JN. How I treat Patients With Thrombotic Thrombocytopenic purpura: Blood 2010;116:4060-9.
3. Burns ER, Lou Y, Pathak A. Morphologic diagnosis of thrombotic thrombocytopenic purpura. Am J Hematol 2004;75:18-21.
4. Copelovitch L, Kaplan BS. The thrombotic microangiopathies. Pediatr Nephrol 2008;23:1761-7
5. Arnold DM, Patriquin CJ, Nazy I. Thrombotic microangiopathies: a general approach to diagnosis and management. CMAJ 2017;189:153-9
6. Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012; 158: 323-35.
7. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002;347:589-600.
8. Tekgündüz E, Yılmaz E, Erkurt MA et all. A multicenter experience of thrombotic microangiopathies in Turkey: The Turkish Hematology Research and Education Group (ThREG)-TMA01 study. Transfus Apher Sci 2018:57;27-30.
9. Huestis DW, Bove JR, Busch S. Practical Blood Transfusion. 3rd ed. Boston: Little, Brown and Company. 1981:315-72.
10. Korkmaz S, Medeni SS, Demirkan F et all. The Turkish Experience With Therapeutic Plasma Exchange: A National Survey. Transfus Apher Sci 2019:58;287-92.
11. Martin JN Jr, Blake PG, Lowy SL, et al. Pregnancy complicated by preeclampsiaeclampsia with syndrome of hemolysis, elevated liver enzymes and low platelet count: How rapid is postpartum recovery? Obstet Gynecol 1990;76:737.
12. Sibai BM, Ramadan MK, Usta I, et al. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLPsyndrome). Am J Obstet Gynecol 1993;169:1000-6.
13. Eser B, Guven M, UnalA et all. The Role of Plasma Exchange in HELLP Syndrome. Clin Appl Thromb Hemost 2005;11:211–17.
14. Erkurt MA, Berber I, Berktas HB. A life-saving therapy in Class I HELLP syndrome: Therapeutic plasma exchange. Transfus Apher Sci. 2015;52:194-8.
15. Zheng X,Chung D,Takayama TK, et al. Structure of von Willenrand factor cleaving protease (ADAMTS 13), a metalloprotelnase involved in trombotic thrombocytopenic purpura. J Biol Chem 2001;276:41059-63.
16. Page EE, Kremer Hovinga JA, Terrell DR, et al. Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Adv 2017;1:590-600.botic thrombocytopenic purpura/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange. Anna Hematol 1995;70:319–23.
18. Smith JW, Weinstein R. Therapeutic apheresis: a summary of current indication categories endorsed by the AABB and American Society for Apheresis. Transfusion 2003;43:820-2.
19. Allford SL, Hunt BJ, Rose P, et al. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 2003;120:556-73.
20. Yildirim C, Bayraktaroğlu Z, Gunay N, et al. The use of therapeutic plasmapheresis in the treatment of poisoned and snake bite victims: an academic emergency department’s experiences. J Clin Apher. 2006;21:219- 23.
21. Szczepiorkowski M, Winters JL, Bandarenko N, et al. Guidelines on the use of therapeutic apheresis in clinical practice evidence based approach from the apheresis applications committee of the American society for apheresis J Clin Apher 2010;25:83-177.
22. Verhave JC, Wetzels JFM, van de Kar NCAJ. Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab. Nephrol Dial Transplant 2014;29:131-41.
23. Campistol JM, Arias M, Ariceta G, et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 2013;33:27-45.